AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-49. (Canceled).

50. (Currently Amended) A method for reducing restenosis following a vascular surgical procedure, the method comprising: locally administering to a human a biocompatible, non-biodegradable sustained release dosage form comprising a cytostatic amount of a therapeutic agent comprising a cytostatic agent, an anti-migratory agent, a cytoskeletal inhibitor, or an anti-matrix agent dispersed in a polymer matrix, wherein said cytostatic amount of said ~~cytostatic~~ therapeutic agent~~, anti-migratory agent, cytoskeletal inhibitor, or anti-matrix agent~~ inhibits a vascular smooth muscle cell activity without killing the cell, and wherein said ~~cytostatic~~ therapeutic agent~~, anti-migratory agent, cytoskeletal inhibitor, and anti-matrix agent are~~ is not heparin, a radioisotope, a nitric oxide-releasing compound, suramin, methotrexate, adriamycin, a protein kinase inhibitor, staurosporin, an antisense oligonucleotide, colchicine, a peptidic inhibitor of a cellular factor that triggers proliferation of a smooth muscle cell or a pericyte, a growth factor inhibitor, a smooth muscle-derived growth factor inhibitor, an endothelial-derived growth factor inhibitor, a platelet homing receptor inhibitor, an integrin inhibitor, triazolopyrimidine, or a prostaglandin.

51. (Cancelled).

52. (Previously presented) The method of claim 50, wherein the vascular surgical procedure comprises placement of a stent.

53. (Previously presented) The method of claim 50, wherein the vascular surgical procedure comprises angioplasty.

54. (Previously Presented) The method of claim 50, wherein the locally administering comprises administering the cytostatic agent, anti-migratory agent, cytoskeletal inhibitor, or anti-matrix agent directly to vascular smooth muscle tissue.

55. (Previously Presented) The method of claim 50, wherein the release of the cytostatic agent, anti-migratory agent, cytoskeletal inhibitor, or anti-matrix agent from the dosage form occurs during or after the vascular procedure.

56. (Previously Presented) The method of claim 50, wherein the cytostatic agent comprises a modified toxin, a radionuclide, a stimulator of the production or activation of TGF-beta, taxol, tamoxifen, TGF-beta, a nuclear enzyme DNA topoisomerase II inhibitor, a DNA polymerase inhibitor, an RNA polymerase inhibitor, an adenyl guanyl cyclase inhibitor, a superoxide dismutase inhibitor, a terminal deoxynucleotidyl-transferase, a reverse transcriptase, or lovastatin.

57. (Previously Presented) The method of claim 50, wherein the cytoskeletal inhibitor comprises a vinblastin, cytochalasin, taxol, taxotere, trichothecene, a modified diphtheria ricin toxin, or *Pseudomonas exotoxin.*

58. (Previously Presented) The method of claim 57, wherein the cytoskeletal inhibitor comprises taxol or taxotere.

59. (Currently Amended) The method of claim ~~57~~ 50, wherein the sustained release dosage form is a microparticulate.

60. (Previously Presented) The method of claim 50, wherein the anti-migratory agent comprises a chemotactic factor inhibitor, a chemotactic factor receptor inhibitor, an intracellular cytoskeletal protein inhibitor, a caffeic acid derivative, nilvadipine, a steroid hormone, taxol, or cytochalasin.

61. (Previously Presented) The method of claim 50, wherein the anti-matrix agent comprises tamoxifen.

62. (Currently Amended) The method of claim 50, wherein the ~~sustained release dosage form~~ therapeutic agent comprises the cytostatic agent.

63. (Currently Amended) The method of claim 50, wherein the ~~sustained release dosage form~~ therapeutic agent comprises the cytoskeletal inhibitor.

64. (Currently Amended) The method of claim 50, wherein the ~~sustained release dosage form~~ therapeutic agent comprises the anti-migratory agent.

65. (Currently Amended) The method of claim 50, wherein the ~~sustained release dosage form~~ therapeutic agent comprises the anti-matrix agent.